Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1–Infected Subjects
The Journal of Infectious Diseases, 08/16/2012
Nettles RE et al. – Administration of BMS–663068 for 8 days with or without ritonavir resulted in substantial declines in plasma HIV–1 RNA levels and was generally well tolerated. Longer–term clinical trials of BMS–663068 as part of combination antiretroviral therapy are warranted.